Compare AEHR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHR | DSGN |
|---|---|---|
| Founded | 1977 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.8M | 819.6M |
| IPO Year | 1997 | 2021 |
| Metric | AEHR | DSGN |
|---|---|---|
| Price | $82.22 | $11.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $29.50 | $15.25 |
| AVG Volume (30 Days) | ★ 2.9M | 957.8K |
| Earning Date | 04-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,968,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.43 | $3.33 |
| 52 Week High | $108.75 | $17.25 |
| Indicator | AEHR | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 39.39 |
| Support Level | $76.71 | $9.25 |
| Resistance Level | $102.48 | $13.54 |
| Average True Range (ATR) | 11.19 | 1.39 |
| MACD | -3.32 | -0.52 |
| Stochastic Oscillator | 16.74 | 15.90 |
Aehr Test Systems is engaged in test systems for burning-in and testing logic, optical, and memory integrated circuits. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets. The Company operates in one business segment, the designing, manufacturing, marketing and selling of advanced test and burn-in products to the semiconductor manufacturing industry in several geographic areas. The company provides production solutions across the product manufacturing flow to improve yield and reliability and has developed and introduced several inventive products, including the ABTSTM and FOX-PTM families of test and burn-in systems and FOX WaferPakTM Aligner, FOX-XP WaferPak Contactor, FOX DiePak Carrier and FOX DiePak Loader.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.